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Abstract The success of treatments for chronic obstructive pulmonary disease (COPD) is evaluated by measuring the 
impact on a range of health outcomes. However; outcome measures differ in their relative importance to the various 
stakeholder groups. Patients are most interested in the impact on quality of life and on mortality, while physicians also value 
information about the effect of treatments on lung function and disease progression. In contrast to patients and physicians, 
healthcare payers take a population perspective, and need to balance the health gains achieved and the costs of treatment, 
If the management of COPD is to be improved, it is important, first, to understand the outcomes of importance to each 
relevant stakeholder group, and then second, to refocus the measures in terms that all stakeholders can value. 
02002 Elsevier Science Ltd 
INTRODUCTION 
A treatment, operation or process can only be 
described as successful if an appropriate change is 
measured in an appropriate outcome. Clearly, in the 
field of medicine, care must be taken that appropriate 
outcome measures are defined. So what are the 
appropriate outcome measures for chronic obstructive 
pulmonary disease (COPD), against which the success 
of different therapeutic approaches can be assessed? 
Different stakeholders are likely to value various 
aspects of treatment quite differently (Table I). 
Treatment approaches may, therefore, be considered 
successful by one group while simultaneously being 
valued less highly by other groups who attach greater 
relative importance to other measures. In these days of 
conflicting priorities, the result may be that patients do 
not receive treatments they would value, because the 
outcomes have not been formulated in terms valued by 
healthcare payers, who consequently do not fund the 
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treatments. If the management of COPD is to be 
improved, it is important, first, to understand the 
outcomes of importance to each relevant stakeholder 
group, and then second, to refocus the measures in 
terms that all stakeholders can value. This involves a 
move away from measures of efficacy, in favour of 
measures of effectiveness (Table 2) (I). Consideration 
of health service cost is also required, so that payers 
can weigh up the balance of costs and benefits of 
different treatment packages. 
This paper considers the outcome measures for 
COPD valued by the different stakeholder groups 
(patients, physicians and healthcare payers), before 
discussing outcome measures that may be particularly 
useful to assess treatment success. 
PATIENT PERSPECTIVE 
Although there have been studies to investigate the 
outcomes that matter to patients with asthma (2), 
comparable information for patients with COPD is not 
available.The impact that COPD has on the patient’s life 
is probably the most important issue, with exacer- 
bations, for example, having a long-term impact (3). 
Patients are unlikely to be interested in arbitrary 
measures of lung function - only on whether or not any 
impairment of lung function has a direct effect on daily 
life. It seems likely that patients want reduced 
exacerbation rates, reduced symptoms and improved 
exercise tolerance - together, these outcomes are likely 
to result in improved quality of life.Yet these outcomes 
are not always detected in clinical trials of therapies for 
COPD, despite empirical evidence of treatment success 
from the patient’s perspective (4). 
To address the need to capture the patient’s 
experience, health status questionnaires can be used, 
such as the St George’s Respiratory Questionnaire 
(SGRQ) (S).The COPD symptom control questionnaire 
(CCQ) is another instrument currently under develop- 
ment to assess symptom control in patients with COPD, 
based on the findings from focus groups and in depth 
interviews held with patients in the U.K. and the 
Netherlands (6) and the opinion of 63 worldwide 
respected clinical experts.The questionnaire is short and 
simple to complete, with just IO questions, designed to 
incorporate outcomes that are important to patients 
and may change after treatment (Table 3). 
A validation study of the CCQ carried out in patients 
with COPD has shown satisfactory internal consistency, 
good correlation with the more complex SGRQ and 
moderate correlation with FEV, (7). Interestingly. 
preliminary results with the CCQ has shown that 
although smoking cessation improves symptoms after 2 
months, functional status is not improved (8), 
demonstrating that functional status is not the same as 
symptoms. 
PHYSICIAN PERSPECTIVE 
From the physician’s perspective, the main problems with 
COPD are: 
?? the irreversible and progressive nature of the disease 
which arises mainly from tobacco use 
?? the increasing incidence and prevalence of the 
condition 
MEASURING SUCCESS OFTREATMENT FOR COPD Sl9 
?? consequent increase in morbidity and mortality 
?? the heavy pressure imposed on health care services. 
Other issues that respiratory specialists, particularly, 
would like to have addressed are summarized in Table 4. 
Outcome measures of importance to physicians when 
managing patients include those of importance to 
patients - quality of life, symptom control and mortality - 
as physicians want to help patients feel better. However, 
physicians also consider other outcomes, such as the 
prevention of disease progression. Presently, there may 
be insufficient data to inform prescribing decisions, but 
waiting for the results of large-scale trials may be 
unacceptable in the face of patients presenting now with 
COPD. With increasing pressure on budgets, physicians 
are also interested in cost-effectiveness of treatment 
approaches for stable COPD. Such evaluation needs to 
consider the impact on all participants in the whole 
management pathway - Gl? nurses, specialists, physio- 
therapists - together with the therapeutic choices and 
information flow. There needs to be co-ordination 
between primary and secondary care, with steps taken 
to reduce the frequency of hospital admissions. 
Compliance with pharmacotherapy should be also 
considered, as this has an important impact on cost- 
effectiveness over the long periods of treatment 
required for COPD. 
HEALTHCARE PAYER PERSPECTIVE 
While patients and physicians make decisions for the 
good of individuals, healthcare payers focus on decision- 
making on the population level. Such decision-makers 
include governments, healthcare insurers, primary care 
trusts, health authorities and health management 
organizations (HMOs). To evaluate the success of 
management approaches, healthcare payers require 
evidence of effects on outcome measures that reflect the 
impact on populations. Such measures may be missing 
from many treatment guidelines, which are often focused 
exclusively on the physician perspective (9). In a recent 
review, 25 guidelines on cost-effectiveness methods were 
identified, seven of which came from healthcare payer 
organizations (IO). Outcome measures stated as 
important to healthcare payers in four countries are 
given in Table 5. Overall, healthcare payers are interested 
in final outcomes (mortality, morbidity), and a clear link 
with final outcomes is required if surrogate outcomes 
are used. Measures must be meaningful and patient- 
centred. Outcome measures of interest to healthcare 
payers making decisions on treatment approaches within 
the therapeutic area of COPD include improvement in 
FEV,, improvement in symptom-free and episode-free 
days, reduction in exacerbations, patient satisfaction and 
improvement in COPD-specific quality of life. 
Healthcare payers also have to make decisions across 
therapeutic areas. Measures of success that are 
appropriate to inform these decisions include impact on 
generic (i.e. not disease-specific) quality of life. Utility 
measures (such as EQ-5D and HUI) are of particular 
value, as they allow comparison between different 
therapeutic areas, and take into account the value placed 
by the population on different health states. 
With responsibility for equitable distribution of 
healthcare budgets, decision-makers at the population 
level must also consider the relative cost of different 
treatment approaches. Although many guidelines state 
that measures of treatment success must also include 
assessment of the costs from the societal perspective, in 
reality the main focus is often on costs to the healthcare 
service (Table 6). Real life data relating to routine care is 
required, with comprehensive and realistic collection of 
health service costs. There is increasing recognition 
among decision-makers that information on treatment 
effectiveness can be provided not only by clinical trials, 
but also by other methods (I I). Modelling is often used 
as a framework to bring together different sources of 
data, though any assumptions used must be clearly 
stated. Generally, healthcare payers require information 
on costs to be presented in disaggregated form, so that 
the impact on various aspects of the health service is 
readily apparent. Measures that combine costs and 
outcomes (such as cost per Quality Adjusted Life Year 
(QALY) and cost per exacerbation avoided) are also 
useful to healthcare payers. 
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COMMON GROUND? QALYs. This measure takes into account all aspects of 
health (life length and quality of life).Yet when asked to 
Misconceptions about the emphasis placed by healthcare choose the best value treatment, a study of physicians 
payers on costs (and cost-effectiveness) of treatments showed that rating was on the basis of additional 
may undermine physician and patient trust in the information on treatment effects, and not on the synthesis 
decisions taken at population level. There is also resulting in a cost/QALY value (Levine, unpublished 
considerable misunderstanding among physicians about observations). Furthermore, physicians may believe that 
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decision-makers rate more highly a treatment with a 
higher cost per QALY in a high-profile therapeutic area, 
such as AIDS, than in a treatment with low cost per 
QALY in a low-profile therapeutic area, such as COPD. 
Perhaps this poor understanding is not surprising as the 
measure of QALY was developed to address the needs 
of healthcare payers and not physicians, but it underlines 
the need for education and mutual understanding. From 
the decision-maker perspective, treatments that result in 
only a small gain in QALY for substantial increase in 
costs, may fail to gain attention, despite the change in 
QALY being of significance to patients. 
If patients and clinicians are to have confidence in the 
decisions made by healthcare payers about which 
treatment approaches to fund and which not to fund, 
there must be agreement on the measures of success 
that are being considered. A measure of treatment 
success that is valued by patients, physicians and 
healthcare payers alike, and is clearly understood by all 
stakeholders, is the impact on exacerbations requiring 
hospitalization. For example, it could be argued that any 
treatment approach that reduces the exacerbation rate 
will be appreciated by patients (because of beneficial 
impact on symptoms and quality of life), physicians 
(because of benefits to patients and impact on healthcare 
resources) and healthcare payers (because hospitali- 
zations are the main cost driver in the management of 
COPD). 
CONCLUSIONS 
In conclusion, it is clear that patients, physicians and 
healthcare payers are likely to place conflicting emphasis 
on the different criteria for measuring the success of 
treatment approaches in COPD. This may result in 
healthcare payers failing to recognize and fund therapies 
that could bring considerable benefits to patients. If the 
management of COPD is to be improved, it is important, 
firstly, to understand the outcomes of importance to 
each relevant stakeholder group, and then secondly, to 
refocus the measures in terms that all stakeholders can 
value. This involves a move away from measures of 
efficacy, in favour of measures of effectiveness, and 
consideration of health service costs. A way forward 
could be increased emphasis on a measure that is valued 
by all stakeholders, for example, the impact on 
exacerbations requiring hospitalization. Treatment 
approaches that reduce exacerbation rates for patients 
with COPD will bring benefits that can be appreciated by 
patients, physicians and healthcare payers alike. 
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